Juno Therapeutics (JUNO) Misses Q4 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. PLTR
4. SPY
5. KTOS
6. AON
7. TMUS
8. LBRX
9. BMY
10. MRK

Go back to Juno Therapeutics (JUNO) Misses Q4 EPS by 6c

Juno Therapeutics Reports Fourth Quarter and 2015 Financial Results

February 29, 2016 4:05 PM EST

On track for approval of JCAR015 as soon as 2017 in relapsed/refractory adult ALL

First clinical milestone met for CD22 CAR T cell product candidate

Multiple trials enrolling using CAR/TCR product candidates to treat solid organ tumors

Celgene collaboration off to a strong start

Strong 2015 year end cash position of $1.22 billion

2016 cash burn guidance of $220 million to $250 million, with $170 million to $195 million in operating burn

Conference call to be held today at 5:00 p.m. Eastern Time

... More